Nongfu Spring founder Zhong Shanshan’s Yangshengtang raises stake in Jinbo Bio

A consumer-health billionaire's vehicle adding exposure to a collagen-biotech name is a signal worth noting: strategic capital from outside pure biotech is moving into the sector, and the market read it as validation given the sharp move and elevated turnover. The effect is concentrated on Jinbo Bio's shareholder base and on how Yangshengtang's intentions are perceived. Whether this first increase becomes a broader accumulation pattern, and whether the premium holds once the initial disclosure-driven enthusiasm fades, is the open question.